



ASX ANNOUNCEMENT

4 March 2025

## Chimeric announces intention to undertake Entitlement Offer

- Intention to raise up to approximately \$3.2 million at \$0.005 per share on a 2 for 5 basis
- 1 new option (exercise \$0.008, expiry 19 December 2025) to be issued for every 1 new share investors subscribe for (subject to shareholder approval)
- Funds will primarily support continued development of Chimeric's CHM CDH17 Phase 1/2 clinical trial
- Opportunity for eligible shareholders to participate at the offer price

**Melbourne, Australia, 4 March 2025:** Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce that it intends to undertake a pro rata non-renounceable Entitlement Offer to raise up to approximately \$3.2 million (before costs) at an offer price of \$0.005 per fully paid ordinary share. This will be completed on the basis of 2 new shares for every 5 existing shares held by eligible shareholders.

As anticipated by the request for a trading halt on 27 February 2025, the Company had intended to announce a capital raise. Per the request for voluntary suspension on 3 March 2025, these discussions were not completed at this time. To lift the voluntary suspension, the Company is announcing today the intention to undertake an entitlement offer.

The offer price of \$0.005 per share represents a 23.1% discount to the last closing price of \$0.0065 (26 February 2025) and a 28.6% discount to the 5-day VWAP of \$0.007.

In addition, 1 new option (issued for nil additional consideration, with an exercise price of \$0.008, and an expiry date of 19 December 2025) will be issued for every 1 new share investors subscribe for under the Entitlement Offer. The issue of options will be subject to shareholder approval, with the intention to seek quotation of options on the ASX.

New shares issued under the Entitlement Offer will rank equally with the existing shares on issue.

The Entitlement Offer provides eligible shareholders with the opportunity to take up new shares proportional to their shareholding and therefore mitigates the effect of dilution. Eligible shareholders who do not take up their entitlement under this offer will not receive any value in respect to those entitlements not taken up. The Offer represents an opportunity for eligible shareholders to participate at the offer price and receive 1 attaching option for nil additional consideration.



Upon distribution of the Entitlement Offer documentation, shareholders will have the ability to apply for 'top up' of additional shares (and attaching options) over and above their pro rata entitlement.

The Company advises that further details are expected to be released on or before Tuesday 18 March 2025.

PAC Partners and Taylor Collison have been appointed as lead managers to the Entitlement Offer.

**Chimeric's CEO Dr Rebecca McQualter said:** "Following our recent news of \$4m of non-dilutionary funding and positive early signs from the CHM CDH17 clinical trial, we're looking forward to continuing this clinical development and moving toward all important data from the Phase 1/2 trial. This Entitlement Offer will aid in those efforts and provides all of our eligible existing shareholders with a special opportunity to participate and continue their support of Chimeric at this pivotal juncture."

### **Use of Funds**

Funds raised from the Entitlement Offer are intended to be applied to:

- CHM CDH17 CAR-T Program: CHM is continuing to dose patients in this Phase 1/2 trial in patients with neuroendocrine tumours, colorectal cancer and gastric cancer.
- CORE NK Platform: In partnership with Case Western University, Chimeric has commenced a novel Phase 1B clinical trial with its CORE NK platform. The trial is the first-ever trial to assess NK cells in combination with Vactosertib in patients with advanced colorectal and blood cancers. In addition, CHM in partnership with MD Anderson Cancer Centre, is evaluating the synergy of NK cell therapy in combination with the current standard of care for blood cancer, Azacitidine and Venetoclax (aza/ven).
- CHM CLTX Program: CHM CLTX is a novel CAR T Therapy currently in Phase 1b clinical trial in recurrent and/or progressive glioblastoma multiforme (GBM – Brain Cancer). Initial positive data from the investigator-initiated trial has been presented.
- General working capital and costs of the capital raising.

### **ABOUT CHIMERIC THERAPEUTICS**

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR-T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.



CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR-T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR-T was published by Dr. Hua and colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR-T therapy developed for the treatment of patients with solid tumours. CLTX CAR-T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

*Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.*

#### **Contact**

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: [investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)

W: [www.chimerictherapeutics.com](http://www.chimerictherapeutics.com)

Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)